ETF Holdings Breakdown of REPL

Stock NameReplimune Group Inc
TickerREPL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS76029N1063
LEI549300AY704NEIRC4K64

News associated with REPL

Barclays PLC Raises Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)
Barclays PLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 167,329 shares of the company’s stock after acquiring an additional 8,838 shares during the quarter. […] - 2025-05-02 09:03:01
Invesco Ltd. Trims Stock Position in Replimune Group, Inc. (NASDAQ:REPL)
Invesco Ltd. cut its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 51.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,006 shares of the company’s stock after selling 92,952 shares during the period. Invesco Ltd.’s holdings in Replimune Group were worth $1,066,000 […] - 2025-05-02 07:30:49
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Wells Fargo & Company MN
Wells Fargo & Company MN boosted its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 102.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 77,371 shares of the company’s stock after acquiring an additional 39,121 shares during the period. Wells Fargo & Company MN’s holdings in Replimune Group were worth $937,000 as […] - 2025-04-30 08:14:51
Legal & General Group Plc Acquires 17,597 Shares of Replimune Group, Inc. (NASDAQ:REPL)
Legal & General Group Plc lifted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 42.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,366 shares of the company’s stock after purchasing an additional 17,597 shares during the […] - 2025-04-29 07:50:50
Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $19.43
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been given an average rating of “Buy” by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target […] - 2025-04-14 05:59:04
Corebridge Financial Inc. Sells 2,284 Shares of Replimune Group, Inc. (NASDAQ:REPL)
Corebridge Financial Inc. trimmed its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 7.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 30,267 shares of the company’s stock after selling 2,284 shares during the period. Corebridge Financial Inc.’s holdings in Replimune Group were worth $367,000 at the end of the most […] - 2025-04-10 08:33:06

REPL institutional holdings

The following institutional investment holdings of REPL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 35,877USD 278,764
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 9,743USD 75,703
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 37,532USD 291,624
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 37,532USD 291,624 7.9%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 213USD 1,655
Total =120,897 USD 939,370
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.